



CASE PH-7382-NP

CERTIFICATE OF MAILING

hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Nancy S. Turover
Type or print name

N S Turover
Signature

Dec 12, 2003
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**IN RE APPLICATION OF: Michael G. Yang****APPLICATION NO: 10/650,358****FILED: August 27, 2003****FOR: Tetrazolylpropionamides as Inhibitors of A-Beta Protein Production**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Respectfully submitted,

Date: *12 Dec. 2003*

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Aldo A. Algieri
Agent for Applicants
Reg. No. 31,697
Phone: (203) 677-6809

FORM RTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. PH-7382-NP


APPLICATION NO. 10/650,358

APPLICANT Michael G. Yang

FILING DATE 27 Aug 2003

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						

FOREIGN PATENT DOCUMENTS

	AC	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AD	WO 00/07995	17 Feb 2000	DU PONT PHARMACEUTICALS CO.			<input type="checkbox"/>	<input type="checkbox"/>
	AE	WO 01/77086	18 Oct 2001	DU PONT PHARMACEUTICALS CO.			<input type="checkbox"/>	<input type="checkbox"/>
	AF	WO 00/38618	6 July 2000	DU PONT PHARMACEUTICALS CO.			<input type="checkbox"/>	<input type="checkbox"/>
	AG	WO 01/92235	6 Dec 2001	DU PONT PHARMACEUTICALS CO.			<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AI	CHAPMAN, P. F., <i>et al.</i> , "Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice", <i>Nature Neurosci.</i> (1999), 2, 271-276
	AJ	DAHLGREN, K. N., <i>et al.</i> , "Oligomeric and Fibrillar Species of Amyloid- β Peptides Differentially Affect Neuronal Viability", <i>J. Biol. Chem.</i> (2002) 277, 32046-32053
	AK	GÖTZ, J., <i>et al.</i> , "Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by A β 42 Fibrils", <i>Science</i> (2001) 293, 1491-1495
	AL	LEWIS, J., <i>et al.</i> , "Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP", <i>Science</i> (2001), 293, 1487-1491
	AM	MCLEAN, C. A., <i>et al.</i> , "Soluble pool of A β -amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease", <i>Ann. Neurol.</i> (1999) 46, 860-866
	AN	SEIFFERT, D., F., <i>et al.</i> , "Presenilin-1 and -2 Are Molecular Targets for γ -Secretase Inhibitors", <i>J. Biol. Chem.</i> (2000) 275, 34086-34091
	AO	SELKOE, D. J., "Alzheimer's Disease: Genes, Proteins, & Therapy", <i>Physiol. Rev.</i> (2001) 81, 741-766
	AP	SELKOE, D. J., "Mechanism of Alzheimer's Disease", <i>Ann. Rev. Cell Biol.</i> (1994) 10: 373-403
	AQ	THAL, D. R., <i>et al.</i> , "Two Types of Sporadic Cerebral Amyloid Angiopathy", <i>J. Neuropath. Exp. Neuro.</i> (2002) 61: 82-293
	AR	WALSH, D. M., <i>et al.</i> , "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation <i>in vivo</i> ", <i>Nature</i> (2002) 416, 535-539
	AS	WOLFE, M. S., "Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential", <i>J. Med. Chem.</i> (2001) 44, 2039-2060
	AT	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.